Trump's Most Favored Nation Drug Pricing Policy Threatens US Competitiveness

Congressional enactment of the most-favored nation drug pricing policy urged by President Trump would gravely harm American innovation and competitiveness. This policy shift threatens to undermine the United States' ability to compete globally in high-value sectors like pharmaceuticals. The move represents a departure from free-market principles that could stifle domestic industry growth.